Congratulations, @MichaelGNanna , on receiving Postdoctoral Affairs Faculty Mentor Award!
Your dedication to mentoring and supporting trainees is truly inspiring. We are honored to have you as a mentor and grateful for your guidance, encouragement, and leadership.
Congratulations, @MichaelGNanna , on receiving Postdoctoral Affairs Faculty Mentor Award!
Your dedication to mentoring and supporting trainees is truly inspiring. We are honored to have you as a mentor and grateful for your guidance, encouragement, and leadership.
What are the biggest challenges in managing cardiogenic shock in older adults?
📣Join our next session of the Cardiovascular Aging Symposium as Dr. Ajar Kochar discusses the evidence gaps, ethical dilemmas, and real-world clinical challenges surrounding cardiogenic shock in the aging population.
📅May 28th, 2026
⏰5:00 – 6:00 PM ET
💻Microsoft Teams:
https://t.co/tsPQG24GQn
Meeting ID: 265 974 903 473 0
Passcode: kz7Gh9UV
@Ajar_Kochar@MichaelGNanna@DrDamluji@heartwiselab
Check out the new JACC commentary from @heartwiselab on dyslipidemia management in older adults, discussing the 2026 guideline updates and the importance of individualized lipid-lowering therapy beyond chronologic age alone.
https://t.co/OopSrYsIK2
@MichaelGNanna@DrDamluji #RaizaRossi @DrAROrkaby@YaleCardiology@YaleIMed@JACCJournals
#CardioTwitter #PreventiveCardiology #GeriCardio
Always so humbling to be at these conferences, surrounded by and learning from some of the biggest names in the field. Honor to even be a tiny part of it. #ACC2026@jmcchiefs@heartwiselab
🎉Congratulations to Kuan-Yu Chi on earning First Runner-Up in the #ACC26 Young Investigator Awards (Clinical Investigation)!
His work, GLP-1 RA Use in Obese Patients With Stable HFrEF: A Target Trial Emulation, adds important real-world evidence on the expanding role of GLP-1 therapies in cardiometabolic disease and heart failure.
Exciting to see our early-career investigators leading impactful research in this rapidly evolving space.
#ACC26 #HeartFailure #GLP1 #CardioTwitter #YoungInvestigators
@MichaelGNanna@DrDamluji@DwagemdwagYu@ACCinTouch@jmcchiefs
Congratulations to our rising star resident, @ZaferAkmanMD, on winning the Best Abstract Award in Geriatric Cardiology at ACC26! 🏆
His work, Calcium Channel Blockers vs Beta Blockers and Risk of Cognitive Decline in Older Adults, highlights the importance of studying cardiovascular therapies with cognitive outcomes in mind, an area underscored by studies such as SPRINT-MIND and further advanced by our ongoing LIVEBETTER clinical trial.
@MichaelGNanna@DrDamluji@YaleCardiology@TonyGuangyuTONG@YaleIMed@TradIMYale #GeriatricCardiology #ACC26 @ACCinTouch
What do the latest ACS Guidelines mean for older adults?
📣Join our next session of the Cardiovascular Aging Symposium as Dr. Sunil Rao, Chair of the 2025 ACS Guidelines, discusses how to apply the latest evidence to older adults. 👵👴one of the fastest-growing and most complex populations in cardiology.
🗓️ March 26th, 2026
⏰ 5:00 – 6:00 PM ET
📍 Cleveland Clinic Foundation Main Campus, J2-223
💻 Microsoft Teams:
https://t.co/tsPQG24GQn
Meeting ID: 265 974 903 473 0
Passcode: kz7Gh9UV
@SVRaoMD@MichaelGNanna@DrDamluji@heartwiselab@ClevelandClinic #ACSGuidelines #GeriatricCardiology #MedEd
HeartWise Lab at #ACC26 🫀
Check out our full schedule! We're excited to share our latest work in cardiovascular prevention, aging, and real-world evidence.
Looking forward to seeing friends, collaborators, and meeting new colleagues in NOLA! ✨
#ACC26@ACCinTouch@heartwiselab@MichaelGNanna@DrDamluji
Research from the @heartwiselab found that under the 2025 AHA/ACC #hypertension guidelines, 11% of adults aged 65 to 79 with stage I hypertension would no longer qualify for blood pressure medication. The new guidelines use the PREVENT-based risk assessment to target treatment for those most likely to benefit and promote more personalized, risk‑based care for older adults. https://t.co/SliIPC9Lrj
@MichaelGNanna@s_mangalesh@drdamluji@arminnouri95@yalemed@yaleimed@yalecardiology@AHAScience